Skip to main content
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
Published Web Location
https://doi.org/10.1038/nn.2632Abstract
The authors have developed a new inhibitor of the enzyme that degrades the endocannabinoid anandamide. This new drug does not cross the blood-brain barrier. It elevates peripheral anandamide only, which, acting on peripheral CB1 receptors, attenuates pain responses in rodents.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.